XOutlier
Download .zipAdd to Chrome

Moderna

@moderna_tx145k followers

Our mission is to deliver the greatest possible impact to people through mRNA medicines.

Open on X
Top outlier
86.3×
Best organic post
Peak views
2.1M
Single post
Bookmarks
4.6k
Across 98 organic posts
Last scan
Oct 17
Community cache
Posts 98 posts
#DatePost↓ OutlierViewsLikesRepostsBookmarks
1May 6, '24Your risk of #LongCOVID rises with each additional infection. A recent study has shown that by their third COVID infection, patients have a 40% chance of developing Long COVID symp86.3×2.1M2.8k1.6k1.3k
2Jan 27, '22ANNOUNCEMENT 📢: We are proud to announce that the first participant has been dosed in the Phase 1 study of mRNA-1644, our experimental #HIV #mRNA #vaccine candidate. Learn more ab67.1×018k6.3k613
3Jan 25, '21We just announced that the Moderna COVID-19 Vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa. Read more61.9×019k5.9k236
4Sep 9, '21Today, we shared positive pre-clinical data demonstrating our ability to combine 6 mRNAs against 3 different respiratory viruses in 1 vaccine: COVID-19 booster + Flu booster + RSV 57.3×015k4.8k552
5Nov 16, '20We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study. Read more:21.5×05.8k1.9k73
6Feb 9, '22What if #mRNA could treat life-threatening #cardiovascular diseases such as #HeartFailure? We are collaborating with @AstraZeneca on an mRNA therapeutic (AZD8601) that encodes for 17.6×0783415295
7Sep 6, '23We announced today clinical trial data for our updated COVID-19 vaccine candidate in humans against BA.2.86 (Pirola), a variant under monitoring. Read more ⬇16.2×397k32711743
8Nov 30, '20We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authoriz16×04.5k1.4k48
9Mar 22, '21We just announced that the Philippines has secured 7 million additional doses of our COVID-19 vaccine through a new supply agreement & partnership with the private sector, brin14.4×04.5k1.1k32
10May 18, '20Summary of our SARS-CoV-2 #vaccine (mRNA-1273) interim Phase 1 data. Read more: #mRNA10.7×02.6k1.2k69
11Mar 16, '21We just announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, our vaccine candidate against COVID-19, in children ag10.4×02.5k82855
13May 15, '24There are more adults ages 35-49 living with #LongCOVID than any other age group. Long COVID can impact everyone, regardless of age or health status. The only way to not get Long C8.8×215k560251131
14Jul 14, '20We just announced interim results from the NIH-led Phase 1 Study of our #mRNA #vaccine against COVID-19 (mRNA-1273) in @NEJM. Read more:8.6×02.3k97027
15Nov 26, '21We just announced our strategy to address the omicron (B.1.1.529) SARS-CoV-2 variant. Read more:7.6×01.9k71182
16Nov 16, '20We just announced a longer shelf life at refrigerated temperatures for mRNA-1273, our COVID-19 vaccine candidate. Read more:5.6×01.7k46034
17May 18, '20We just announced positive interim Phase 1 data for our mRNA vaccine (mRNA-1273) against novel coronavirus. Read more:5.1×01.4k54322
18Feb 9, '21We just announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government of Taiwan for 5 million doses and another with the government of Colombia for 10 m4.8×01.5k48311
19Jun 8, '22ANNOUNCEMENT 📢: A 50 µg booster dose of our Omicron-containing bivalent #COVID19 #booster candidate, mRNA-1273.214, demonstrated superior antibody response against the #Omicron va4.5×01.2k41368
20Nov 30, '20Update: Moderna’s data for the Emergency Use Authorization request for mRNA-1273 has been submitted to the U.S. FDA.4.4×01.5k30912
21Dec 19, '20We just announced that the FDA has authorized the Moderna COVID-19 Vaccine in the U.S. for emergency use to prevent COVID-19 in individuals 18 and over. The Moderna COVID-19 Vaccin4.4×01.3k42110
22Jul 14, '20Read more in our press release here:4.4×01.3k40318
23Mar 14, '23Today we announced that Phase 2 data on mRNA-4156/V940, our investigational personalized #mRNA #cancer vaccine, will be presented at the 2023 American Association of Cancer Researc4.0×97k4127413
24Jan 31, '22BREAKING: The @FDA has approved the Biologics License Application (BLA) for SPIKEVAX™ (COVID-19 Vaccine, mRNA) to prevent #COVID19 in individuals 18 years of age and older.3.8×062222833
25Mar 7, '22We're announcing that with the assistance of the U.S. Government, we have entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish #Keny3.5×074449012
26Jul 27, '20We just announced that the Phase 3 study of mRNA-1273, our vaccine candidate against COVID-19 has begun. The Phase 3 study being conducted in collaboration with @NIH and @BARDA. Re3.4×091036310
27Feb 16, '21We just announced a supply update for the Moderna COVID-19 Vaccine in the United States, reporting that 45.4 million doses have been supplied to the U.S. Government to date. Read m3.4×01.2k24312
28Dec 17, '20We just confirmed that the @US_FDA VRBPAC recommended that the FDA grant an Emergency Use Authorization for our COVID-19 vaccine candidate, mRNA-1273. 20 VRBPAC members recommended3.3×01k2937
29Mar 16, '20We just announced that the first participant has been dosed in the NIH-led Phase 1 study of our #mRNA vaccine (mRNA-1273) against novel coronavirus3.3×07853558
30Jul 26, '20We just announced an expansion of our agreement with @BARDA for up to an additional $472 million to support our late stage clinical development of mRNA-1273, including the executio3.2×087233912
31Mar 10, '21We just announced that the first participants have been dosed with our modified COVID-19 vaccines, designed to address the potential need for booster vaccine candidates, in an amen3.1×090929036
32Feb 24, '20We just announced that we have shipped vials of mRNA-1273, the Company’s vaccine against the novel coronavirus, to the NIH to be used in the planned Phase 1 study in the U.S.3.1×051648917
33Apr 28, '22We're announcing that we have submitted a request for #EUA for our #COVID19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S3.0×07202349
34Mar 23, '22We're announcing positive interim data from the Phase 2/3 KidCOVE study of our #COVID19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of ag2.9×071927418
35May 9, '24Long COVID is having a major impact on the productivity of health systems and the wider workforce. One recent estimate suggests that #LongCOVID may have cut labor supply in the Eur2.9×70k598238107
36Dec 20, '21The authorized 50 µg booster of mRNA-1273 increased neutralizing antibody levels against Omicron ~37-fold compared to pre-boost levels & a 100 µg dose of mRNA-1273 increased ne2.8×059629341
37Aug 11, '20Breaking: Moderna announces a supply agreement with the U.S. government to secure an initial 100 million doses of mRNA-1273 for up to $1.525 billion with option granted to U.S. gov2.6×06922417
38Jul 11, '22Our Omicron-containing bivalent #booster candidate, mRNA-1273.214, demonstrates significantly higher neutralizing antibody response against #Omicron subvariants BA.4/5 compared to 2.4×072020347
39Apr 13, '21Moderna's statement on CVST or thrombotic events.2.4×061923325
40May 25, '21We just announced that the Phase 2/3 study of our COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint. In the study, no cases of COVID-19 were observed in p2.2×062619613
41Jun 22, '22One month after administration in previously vaccinated and boosted participants, a 50 µg #booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the2.2×063816634
43May 3, '21We just announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delive2.0×06531625
44Feb 5, '21Moderna is developing an investigational mRNA vaccine against cytomegalovirus. Learn more about #CMV here: #StopCMV #CMVawareness2.0×072412712
45Dec 29, '20We just confirmed that the Company is engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine. Rea2.0×04512775
46Dec 11, '20We just announced the U.S. gov't has exercised the 1st option for an additional 100 million doses of our COVID-19 vaccine candidate, which will be delivered in Q2 2021. Read more:1.9×06041365
47Nov 26, '21And third, we are rapidly advancing a Omicron-specific booster candidate (mRNA-1273.529).1.9×047914012
48Aug 5, '21Emerging real-world evidence confirms Moderna efficacy against COVID-19 wild-type virus and variants of concern (VOCs), including Alpha, Beta/Gamma and Delta VOC, even after partia1.8×041922416
49Oct 22, '20We just announced that we have completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, our vaccine candidate against COVID-19. Read more:1.7×05461123
50Jan 26, '21This morning, we announced a U.S. supply update for the Moderna COVID-19 Vaccine, reporting that 30.4 million doses have been supplied to the U.S. Government to date. We remain on 1.7×05451394
51Jan 8, '21We just announced that the UK’s MHRA has approved our mRNA vaccine against COVID-19 for use. The UK government also secured an additional 10 million doses of the COVID-19 Vaccine M1.6×05041474
52Apr 19, '22A 50 µg #booster dose of our first bivalent booster #vaccine candidate, mRNA-1273.211, demonstrated superiority against Beta, Delta and #Omicron variants of concern one month after1.6×042413835
53May 12, '21We announced a new supply agreement with Australia for 25 million doses of our COVID-19 vaccine, including 10 million doses of our vaccine against the ancestral strain for in 2021 1.6×04371266
54Jun 12, '20We are pleased to share a preprint of the preclinical manuscript for our #vaccine against #SARS-CoV-2 to potentially prevent #COVID19 disease. We thank the NIAID team for their col1.6×041617813
55Oct 3, '21Respiratory viruses are a leading cause of many hospitalizations and deaths. We believe Moderna could be first to market with a COVID + Flu + RSV booster vaccine. A single vaccine 1.6×049810814
56Dec 1, '20Update: The European Medicines Agency has received Moderna’s application for conditional marketing authorization of our COVID-19 vaccine1.6×05651032
57Mar 29, '21100 days after receiving Emergency Use Authorization from the U.S. FDA, we are proud to share that we’ve shipped the 100-millionth dose of our COVID-19 vaccine to the U.S. Governme1.5×05271182
58Dec 23, '20We just announced that Health Canada has authorized the Moderna COVID-19 Vaccine in Canada. Read more:1.5×05231244
59Jan 25, '21Now available as a preprint on bioRxiv: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. Read more here:1.5×042915615
60Sep 17, '20To provide additional transparency in context of pandemic, the protocol for the Phase 3 COVE study of mRNA-1273 being conducted in collaboration with the NIH and BARDA is now avail1.5×036616019
61Jan 26, '22ANNOUNCEMENT 📢: Given the long-term threat demonstrated by Omicron’s immune escape, we are pleased to announce that the first participant has been dosed in the Phase 2 study of ou1.5×035110412
62Dec 24, '20Moderna’s statement on variants of the SARS-CoV-2 virus:1.5×040815116
63Aug 23, '22We have completed our submission to the U.S. FDA for emergency use authorization for our BA.4/BA.5 #Omicron-targeting #bivalent #COVID19 booster #vaccine, mRNA-1273.222. Read more:1.5×047412619
64Aug 11, '22ANNOUNCEMENT 📢: The first participant has been dosed in a Phase 2/3 trial of mRNA-1273.222, a bivalent #COVID19 #booster vaccine candidate targeting the original and #Omicron BA.41.5×05189717
65Jan 5, '22ANNOUNCEMENT 📢: We're proud to announce that the first participant has been dosed in the Phase 1 study of our Epstein-Barr Virus (#EBV) #mRNA #vaccine candidate.1.5×043310115
66Jan 25, '21We also announced that out of an abundance of caution, we are launching a clinical program to boost immunity to emerging variants. Learn more:1.5×04241528
67Dec 10, '20We just announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, our vaccine candidate against COVID-19, in adolescents ages 12 to less1.5×04331075
68Sep 3, '21We are pleased to announce that today we completed our submission to the @US_FDA, which we began on Wednesday, for the evaluation of a booster dose of the Moderna COVID-19 vaccine.1.5×04861053
69Oct 8, '20While the pandemic continues, Moderna will not enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic. Read our statement here:1.4×03971196
70Nov 11, '20We just announced that we have completed case accrual for the first planned interim analysis of mRNA-1273, our mRNA vaccine against COVID-19. Read more:1.4×04271018
71Aug 21, '20We are pleased to share that as of today, Friday, August 21st, 13,194 participants have been enrolled in the COVE Phase 3 study of mRNA-1273. Find out more about the trial here: . 1.4×04181119
72May 29, '20We just announced that the first participants in each age cohort have been dosed in the Phase 2 study of our mRNA vaccine (mRNA-1273) against novel coronavirus. Read more: #mRNA1.4×03911443
73Jan 5, '21We just announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. Read more here:1.4×04331162
74Apr 27, '20We just announced that we have submitted an IND application to the U.S. FDA for a Phase 2 study of our mRNA Vaccine (mRNA-1273) against novel coronavirus. Read more:1.4×04001224
75Aug 1, '21Today, we are celebrating RNA Day! Every day, our bodies use RNA to make proteins to carry out activities like eating, breathing, and working. Happy #RNA Day! #Science1.4×04751148
76Jul 2, '20July 2 statement from Moderna1.4×03881163
77Mar 14, '22ANNOUNCEMENT 📢: We are proud to announce that the first participant has been dosed in the Phase 1 study of mRNA-1574, our experimental human immunodeficiency virus (#HIV) trimer #1.4×034912510
78Dec 18, '20We just announced that the European Commission has exercised its option to purchase an additional 80 million doses of mRNA-1273, our COVID-19 vaccine candidate, bringing its confir1.4×04341154
79Apr 29, '21Ongoing development data related to the current formulation of our COVID-19 vaccine could support a 3-month refrigerated (2-8°C) shelf life for the vaccine in alternative formats t1.3×04471234
80Dec 7, '20This morning, we announced that the Canadian government has increased its confirmed order commitment by 20 million doses of mRNA-1273, our vaccine candidate against COVID-19, bring1.3×0405982
81Aug 27, '21We are pleased to share that Health Canada has authorized our #mRNA COVID-19 vaccine in Canada to include immunization to prevent COVID-19 caused by the SARS-CoV-2 virus in adolesc1.3×0431982
82Nov 25, '20We just announced that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, with the option to increase their purchase to a total of up to 1601.3×0431903
83Oct 14, '20We just announced that we have received confirmation of eligibility for submission of a Marketing Authorization Application to the European Medicines Agency for mRNA-12731.3×04181203
84Feb 24, '21We also announced that we have increased our 2021 base plan to 700 million doses and we working to supply up to 1 billion doses in 2021. Read more:1.3×04671042
85Mar 6, '21Earlier today, we announced a supply agreement to provide 13 million doses of COVID-19 Vaccine Moderna to the Philippines. Read more:1.2×04221002
86Feb 11, '21This evening, we announced that the U.S. government has purchased an additional 100 million doses of Moderna’s COVID-19 Vaccine, bringing its confirmed order commitment to 300 mill1.2×04371013
87Feb 24, '21Earlier today we announced that we shipped our variant-specific vaccine candidate, mRNA-1273.351, to the @NIH for a Phase 1 clinical trial that will be led and funded by the NIH’s 1.2×03421229
88Aug 5, '20Today, we are sharing an important update about our protocol for the Phase 3 COVE Study of mRNA-1273, our vaccine candidate against COVID-19.1.2×0335951
89Apr 13, '21New preclinical data shows variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. Read m1.2×0388999
90Oct 14, '21We are grateful for the opportunity to present the clinical data package for our COVID-19 booster vaccine to the FDA’s advisory committee today. We thank the committee for their re1.1×0381905
91Dec 19, '20Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at1.1×0352835
92Sep 4, '20We are pleased to share that as of today, Friday, September 4th, 21,411 participants have been enrolled in the COVE Phase 3 study of mRNA-1273. Find out more about the trial here: 1.1×0344915
93Dec 3, '20We just provided an update on mRNA-1273, our COVID-19 vaccine candidate, including interim durability data from the NIH-led Phase 1 study of mRNA-1273 and a production update. Read1.1×0363807
94Aug 24, '20We just announced that we have concluded advanced exploratory talks with the European Commission to supply 80 million doses of mRNA-1273. Read more here:1.1×0344972
95Oct 7, '21Today, we announced that we will build a state-of-the-art #mRNA facility in Africa to manufacture up to 500 million doses per year. Since our founding in 2010, our mission has been1.1×0340635
96Apr 7, '21This evening, we are highlighting the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in @NEJM . Read more:1.0×0336766
97Nov 24, '20Moderna confirms advanced discussions with the European Commission to purchase an initial 80 million doses of mRNA-1273 with the option to purchase up to an additional 80 million d1.0×0356572
98Mar 15, '21We just announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, our next generation COVID-19 vaccine candidate. Read more:0.9×0320655
99Nov 17, '20We just announced a supply agreement with the United Kingdom government to supply mRNA-1273, our mRNA vaccine against COVID-19 if approved for use. Read more:0.9×0335464
100Dec 13, '21We just announced an agreement in principle with the Australian Government to build a state-of-the-art #mRNA vaccine manufacturing facility in Victoria, Australia including access 0.9×0339506

Scan another creator

@
@karpathy@levelsio@paulg@naval@marclou@illyism

Run this on any account.

XOutlier builds this table for every public profile you open on x.com, with live data and every post, not just the top 50.

Add to Chrome Download .zip